Research Article Open Access

Delivery of Piroxicam With A Mucoadhesive Buccal Tablet: In Vitro, Ex Vivo and In Vivo Evaluation

Abstract

Piroxicam (PX) is one of the most potent non-steroidal, antiinflammatory agents which also exhibit anti-pyretic activity in various types of non-rheumatic pains. Although the drug is well absorbed following oral administration, gastric irritation is still the most serious adverse effect. Thus there is a need for an alternative drug delivery system with better GI tolerability. Buccal administration of drugs provides a convenient route of administration for both systemic and and local actions and bypasses first-pass effects and avoids GI side effects. Therefore the aim of this study was to develop buccal tablets of piroxicam by using hydroxypropyl methylcellulose and chitosan as mucoadhesive agents. Tablets were prepared with direct compression method and evaluated for physical properties. In vitro dissolution studies showed that the release rate of PX from the formulations affected by type and ratio of polymers. The release mechanism of PX from buccal tablets follows diffusive mechanism with first order and Higuchi release kinetics. In vivo studies of optimum buccal tablet formulation carried out on human healthy volunteers showed that the relative bioavailability of PX was 67.52 ± 21.47%. These results demonstrate that buccal tablet formulation of PX seems to be an alternative drug delivery for patients especially suffering from GI disturbances

Ali Riza Kepsutlu, Cetin Tas, Ayhan Savaser, Yalcin Ozkan and Tamer Baykara

To read the full article Download Full Article | Visit Full Article